In Depth: Performance Comparison of OncoBEAM™ RAS CRC and Idylla™ ctKRAS Liquid Biopsy Testing for KRAS Mutation Detection Presented at ASCO GI 2018
In: PR Newswire Europe, 2018-01-22, S. 4
Zeitungsartikel
Zugriff:
HAMBURG, Germany, January 22, 2018 /PRNewswire/ -- Sysmex Inostics, a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today highlights results presented at the American Society of Clinical Oncology's Gastrointestinal Cancer Symposium (ASCO GI) comparing plasma KRAS mutation detection performance between two commercial liquid biopsy testing platforms, OncoBEAM™ RAS CRC and Idylla™ ctKRAS Mutation Test...
Titel: |
In Depth: Performance Comparison of OncoBEAM™ RAS CRC and Idylla™ ctKRAS Liquid Biopsy Testing for KRAS Mutation Detection Presented at ASCO GI 2018
|
---|---|
Zeitschrift: | PR Newswire Europe, 2018-01-22, S. 4 |
Veröffentlichung: | 2018 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|